Astrana Health, Inc. ASTH
36.37
1.93
5.60%
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 43.6×
Follow ASTH
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 5.03% | 3.86% | 2.98% | 1.27% |
+8 more TTM periods Free account |
|
| 2.18% | 1.64% | 1.26% | 0.54% | ||
ROIC |
4.56% | 3.96% | 3.50% | 2.77% | |
Return on Tangible Assets |
17.32% | 9.50% | 7.36% | 3.08% | |
Average Days of Receivables |
46.45 | 51.28 | 46.19 | 49.29 | |
Free Cash Flow per Share |
1.92 | 3.17 | 2.13 | 1.97 | |
Free Cash Flow |
94.38 | 154.99 | 104.49 | 96.96 | |
Capital Expenditures |
(13.49) | (11.04) | (10.11) | (9.57) | |
Piotroski F-Score |
5.00 | 4.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
4.95% | 7.15% | 5.07% | 4.63% | |
Accounts Receivable Turnover |
9.00 | 8.56 | 8.75 | 9.39 | |
Accounts Payable Turnover |
18.83 | 19.27 | 18.81 | 17.07 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
26.07 | 25.65 | 25.18 | 29.45 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.35) | (0.38) | (0.39) | (0.68) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
6.20% | 6.67% | 6.83% | 6.86% | |
Share Based Compensation of Revenue |
1.06% | 1.15% | 1.21% | 1.47% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.66 | 5.49 | 5.10 | 11.17 | |
Depreciation/Fixed assets |
1.08 | 0.99 | 0.87 | 0.73 | |
Capex/Depreciation |
(0.20) | (0.19) | (0.20) | (0.23) | |
Revenue per Share |
78.27 | 72.18 | 64.83 | 58.85 | |
Operating CF per Share |
2.20 | 3.40 | 2.34 | 2.16 | |
Capex per Share |
(0.27) | (0.23) | (0.21) | (0.19) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
1.05% | 0.86% | 0.71% | 0.33% |
Columns are period end dates